Editor's PickMarket News

Ketamine One says its IRP clinic using NeuroCatch Platform to measure brain function in injured veterans

Ketamine One (NEO:MEDI) Capital Limited (LSE:CAPD, FRA:C8D), a consolidator of medical clinics and aspiring leader in mental health treatments, touted the continued success of the Health Canada-approved advanced brain-scanning NeuroCatch Platform, being used at its Integrated Rehab and Performance Limited (IRP) clinic in Victoria, British Columbia.  The Vancouver-based company said IRP has been an “early adopter” of NeuroCatch’s brain-scanning technology since September 2020, in an effort to better understand brain health and neurocognitive function in patients.  “NeuroCatch continues to differentiate IRP from other rehabilitation clinics, along with its unique focus on patients from the Canadian Armed Forces, the Royal Canadian Mounted Police and various first responder organizations,” said the company.  READ: Ketamine One Capital appoints capital markets veteran Adam Deffett as interim CEO NeuroCatch is expected to remain a key part of IRP’s offering as Ketamine One expands its network to new veteran-centric markets across Canada. “Unique offerings such as NeuroCatch help Ketamine One’s clinicians create more tailored treatment plans for patients,” noted the company. Platforms like NeuroCatch are also important as Ketamine One embarks on embracing digital therapeutics as a core element of its competitive strategy. “Psychedelics-focused research, a growing network of medical clinics, a suite of patient treatment options and digital therapeutics are all being brought together to create a unique mental health platform under Ketamine One,” said the company. In 2019, Health Canada first approved the NeuroCatch Platform, a Class II medical device developed by HealthTech Connex that conducts a rapid 6-minute scan to measure and report on cognitive brain function. It is an easy-to-use rapid neuro-physiological brain function assessment system, that provides doctors with objective measurements of specific brain functions: auditory sensation, basic attention and cognitive processing. According to the company, researchers and clinicians use the technology to get more insight into a range of neurological conditions like concussion and brain injury; dementia and neurological disease; post-traumatic stress disorder (PTSD) and mental health; and brain performance and human optimization. “Embracing technology is essential for improving our patients’ outcomes at IRP and giving them the best care throughout their healing and recovery processes. The use of NeuroCatch enables our staff to customize treatment plans and track improvements in brain health of our patients,” said IRP founder CEO Steven Inglefield in a statement. “Ketamine One’s continued integration of industry-leading clinics and the most advanced treatment options give clinicians greater insights into every patient’s care, while the company’s research assets provide the ability to stay at the forefront of breakthrough treatments and technologies,” he added. Aside from IRP, NeuroCatch is also collaborating with Alberta Children’s Hospital, CAA Hockey, Helius Medical Technologies (CSE:HSM), Kids Brain Health Network, Mayo Clinic and Toronto Rehabilitation Institute. Contact the author Uttara Choudhury at uttara@proactiveinvestors.com Follow her on Twitter: @UttaraProactive